Valuation: Avenue Therapeutics, Inc.

Market Cap 12.69L 11.33L 10.47L 9L 17.74L 12Cr 18.04L 1.26Cr 49.86L 6.31Cr 47.61L 46.6L 20Cr P/E 2024
-0.22x
P/E 2025 -0.73x
Enterprise Value -15.86L -14.17L -13.09L -11.86L -22.19L -15Cr -22.56L -1.57Cr -62.35L -7.89Cr -59.54L -58.27L -25Cr EV / Sales 2024
-
EV / Sales 2025 -4,91,128x
Free-Float
86.49%
Yield 2024 *
-
Yield 2025 -
1 day+46.67%
1 week+2.33%
Current month+10.00%
1 month-12.00%
3 months+59.63%
6 months-33.33%
Current year-35.31%
1 week 0.35
Extreme 0.35
0.44
1 month 0.27
Extreme 0.2695
0.49
Current year 0.15
Extreme 0.15
0.9
1 year 0.15
Extreme 0.15
0.97
3 years 0.15
Extreme 0.15
33.74
5 years 0.15
Extreme 0.15
2,081.25
10 years 0.15
Extreme 0.15
13,882.3
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2022
Chief Executive Officer 36 31/03/2022
Investor Relations Contact - -
Director TitleAgeSince
Chairman 71 09/02/2015
Director/Board Member 69 01/08/2015
Chairman 68 07/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
02/01/26 FreeCompany 1,11,209 3.4934%
31/03/25 FreeCompany 33,724 1.6419%
31/12/24 OtherCompany 2,94,800 15.4214%
Change 5-day change 1-year change 3-year change Capi.($)
+46.67%+2.33%-38.05%-98.49% 12.69L
+2.41%+0.29%+39.41%+73.38% 6.47TCr
+0.79%+8.06%+10.98%+79.27% 5.48TCr
+0.35%+3.36%+9.54%+100.63% 5.35TCr
+0.57%+5.31%+28.78%+51.83% 4.6TCr
-1.18%+1.28%+18.86%+126.06% 4.29TCr
-0.60%+1.74%+219.57%+830.79% 4.01TCr
+0.05%+0.21%+18.06%+48.50% 3.35TCr
+0.22%-8.29%+23.12%+3.15% 2.4TCr
+13.01%+18.76%+61.44%+48.87% 2.37TCr
Average +6.23%+2.17%+39.17%+126.40% 3.83TCr
Weighted average by Cap. +1.27%+2.73%+44.92%+152.49%

Financials

2024 2025
Net sales - 1.4 1.25 1.16 1.05 1.96 133.28 2 13.94 5.52 69.83 5.27 5.16 220.16
Net income -1.17Cr -1.04Cr -96.12L -87.11L -1.63Cr -110.61Cr -1.66Cr -12Cr -4.58Cr -58Cr -4.37Cr -4.28Cr -182.71Cr -29.09L -25.98L -24L -21.75L -40.69L -28Cr -41.36L -2.89Cr -1.14Cr -14Cr -1.09Cr -1.07Cr -46Cr
Net Debt -25.94L -23.16L -21.4L -19.39L -36.28L -25Cr -36.88L -2.58Cr -1.02Cr -13Cr -97.35L -95.28L -41Cr -28.55L -25.5L -23.55L -21.34L -39.93L -27Cr -40.59L -2.83Cr -1.12Cr -14Cr -1.07Cr -1.05Cr -45Cr
Projected Income Statement - Annual - Avenue Therapeutics, Inc.
Logo Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Employees
1
Date Price Change Volume
23/26/23 $0.3850 -4.75% 234

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avenue Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATXI Stock